Autologous Stem Cell Mobilization in the Age of PLERIXAFOR (cas 110078-46-1)
-
Add time:08/13/2019 Source:sciencedirect.com
BackgroundAutologous stem cell transplantation remains important in the treatment of myeloma and relapsed lymphoma. Plerixafor has been shown to significantly enhance stem cell mobilization but is very expensive.
We also recommend Trading Suppliers and Manufacturers of PLERIXAFOR (cas 110078-46-1). Pls Click Website Link as below: cas 110078-46-1 suppliers
Prev:A Pilot, Exploratory, Randomized, Phase II Safety Study Evaluating Tumor Cell Mobilization and Apheresis Product Contamination in Patients Treated with Granulocyte Colony-Stimulating Factor Alone or Plus PLERIXAFOR (cas 110078-46-1)
Next:PLERIXAFOR (cas 110078-46-1) and related macrocyclic amines are potential drug candidates in treatment of malaria by “filling the flap” region of plasmepsin enzymes) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- PLERIXAFOR (cas 110078-46-1) and related macrocyclic amines are potential drug candidates in treatment of malaria by “filling the flap” region of plasmepsin enzymes08/14/2019
- A Pilot, Exploratory, Randomized, Phase II Safety Study Evaluating Tumor Cell Mobilization and Apheresis Product Contamination in Patients Treated with Granulocyte Colony-Stimulating Factor Alone or Plus PLERIXAFOR (cas 110078-46-1)08/12/2019
- Hematopoietic progenitor cell mobilization with “just-in-time” PLERIXAFOR (cas 110078-46-1) approach is a cost-effective alternative to routine PLERIXAFOR (cas 110078-46-1) use08/11/2019
- Mobilization of Hematopoietic Progenitor Cells for Autologous Transplantation Using Pegfilgrastim and PLERIXAFOR (cas 110078-46-1): Efficacy and Cost Implications08/10/2019
- Mobilization of Leukemic Cells Using PLERIXAFOR (cas 110078-46-1) as Part of a Myeloablative Preparative Regimen for Patients with Acute Myelogenous Leukemia Undergoing Allografting: Assessment of Safety and Tolerability08/09/2019
- Etoposide + Granulocyte Colony-Stimulating Factor and Optional PLERIXAFOR (cas 110078-46-1) in Patients Who Failed Chemomobilization with or without PLERIXAFOR (cas 110078-46-1)08/08/2019
